BIO-11006 Inhalation Solution: Phase IIa data

The double-blind, U.S. Phase IIa BREATH 1 trial in 172 patients with moderately severe COPD showed that twice-daily 75 mg BIO-11006

Read the full 213 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE